RxDoctor Payments Data

Emmanuel Sarmiento, MD

Allergy · Greenville, SCNPI 1396747390

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $255,892 of the $287,447 with a category attached, or 89.0%. 48 manufacturers reported payments, led by AstraZeneca at 56.4% of the total.

$287,447in general payments, 2019–2025

Across 1,089 payments — averaging $263.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$162K
  • GSK$96K
  • Regeneron Healthcare Solutions, Inc.$12K
  • Sanofi$8K
  • CSL Behring$2K
  • Pfizer$1K
  • plus $7K from 42 others

What the payments were for

  • Speaking & faculty fees$255,89289%
  • Travel & lodging$8,1803%
  • Food & beverage$23,1718%
  • Education$2040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$889,783
Medicare patients
578
Services billed
42,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab38$161,726
TezspireTezepelumab-Ekko25$110,845
XolairOmalizumab36$87,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$81,484
Breo ElliptaFluticasone/Vilanterol105$55,526
SymbicortBudesonide/Formoterol Fumarate74$25,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$23,991
AirsupraAlbuterol Sulfate/Budesonide13$13,324
Arnuity ElliptaFluticasone Furoate27$8,660
Epinephrine51$7,165
Albuterol Sulfate HfaAlbuterol Sulfate224$6,530
QnaslBeclomethasone Dipropionate16$5,840
RyaltrisOlopatadine Hcl/Mometasone17$5,558
Montelukast Sodium477$4,873
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$4,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Airsupra$162,164$173,523141 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$96,164$145,670233 claims
Hikma Pharmaceuticals USAEpinephrine, Ryaltris$236$12,72368 claims
Teva Pharmaceuticals USA, Inc.Qnasl$348$5,84016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →